Jason Gerberry
Stock Analyst at B of A Securities
(4.19)
# 429
Out of 5,161 analysts
166
Total ratings
60.33%
Success rate
10.37%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $263 → $275 | $180.32 | +52.51% | 7 | Feb 25, 2026 | |
| HRMY Harmony Biosciences Holdings | Maintains: Underperform | $32 → $28 | $27.79 | +0.76% | 3 | Feb 25, 2026 | |
| ALKS Alkermes | Maintains: Neutral | $33 → $34 | $27.64 | +23.01% | 10 | Feb 20, 2026 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $26.86 | +4.24% | 5 | Dec 15, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $62 → $81 | $55.01 | +47.25% | 4 | Dec 9, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $86 → $97 | $72.34 | +34.09% | 7 | Dec 9, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $29 → $32 | $29.30 | +9.22% | 15 | Dec 9, 2025 | |
| OCS Oculis Holding AG | Maintains: Buy | $30 → $29 | $27.10 | +7.03% | 4 | Nov 13, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $28 → $32 | $18.18 | +76.07% | 2 | Aug 26, 2025 | |
| IMVT Immunovant | Maintains: Buy | $33 → $30 | $24.99 | +20.05% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $49 | $9.91 | +394.45% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $173 → $176 | $154.12 | +14.20% | 6 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 → $1 | $2.24 | -55.36% | 4 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $23 | $37.58 | -38.80% | 2 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $46 | $41.17 | +11.73% | 3 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $157 → $137 | $56.21 | +143.73% | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $10 | $13.80 | -27.54% | 3 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $23.39 | +28.26% | 2 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $100 | $114.29 | -12.50% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $10.55 | +127.49% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $31.93 | -2.91% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $550 | $1.34 | +40,944.78% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $57.90 | -3.28% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $977.25 | -48.84% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $2.47 | +264.37% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $6.33 | +294.94% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.63 | +206.75% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $5.05 | +434.65% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.69 | +1,083.43% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $100 | $6.15 | +1,526.02% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $225.37 | -57.85% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $58.95 | +1.78% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $115.91 | -22.35% | 11 | Oct 17, 2019 |
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $263 → $275
Current: $180.32
Upside: +52.51%
Harmony Biosciences Holdings
Feb 25, 2026
Maintains: Underperform
Price Target: $32 → $28
Current: $27.79
Upside: +0.76%
Alkermes
Feb 20, 2026
Maintains: Neutral
Price Target: $33 → $34
Current: $27.64
Upside: +23.01%
Pfizer
Dec 15, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $26.86
Upside: +4.24%
Arrowhead Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $62 → $81
Current: $55.01
Upside: +47.25%
Ionis Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $86 → $97
Current: $72.34
Upside: +34.09%
Teva Pharmaceutical Industries
Dec 9, 2025
Maintains: Buy
Price Target: $29 → $32
Current: $29.30
Upside: +9.22%
Oculis Holding AG
Nov 13, 2025
Maintains: Buy
Price Target: $30 → $29
Current: $27.10
Upside: +7.03%
Amphastar Pharmaceuticals
Aug 26, 2025
Maintains: Neutral
Price Target: $28 → $32
Current: $18.18
Upside: +76.07%
Immunovant
Aug 12, 2025
Maintains: Buy
Price Target: $33 → $30
Current: $24.99
Upside: +20.05%
Aug 12, 2025
Maintains: Buy
Price Target: $50 → $49
Current: $9.91
Upside: +394.45%
Aug 5, 2025
Maintains: Buy
Price Target: $173 → $176
Current: $154.12
Upside: +14.20%
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $2.24
Upside: -55.36%
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $37.58
Upside: -38.80%
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $41.17
Upside: +11.73%
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $56.21
Upside: +143.73%
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $13.80
Upside: -27.54%
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $23.39
Upside: +28.26%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $114.29
Upside: -12.50%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $10.55
Upside: +127.49%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $31.93
Upside: -2.91%
Mar 25, 2024
Maintains: Buy
Price Target: $600 → $550
Current: $1.34
Upside: +40,944.78%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $57.90
Upside: -3.28%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $977.25
Upside: -48.84%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $2.47
Upside: +264.37%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $6.33
Upside: +294.94%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.63
Upside: +206.75%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $5.05
Upside: +434.65%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.69
Upside: +1,083.43%
Jul 15, 2020
Downgrades: Neutral
Price Target: $170 → $100
Current: $6.15
Upside: +1,526.02%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $225.37
Upside: -57.85%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $58.95
Upside: +1.78%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $115.91
Upside: -22.35%